3O
3O8.F Omeros Corporation
- Market cap
- EUR 1.11B
- P/E
- 14.3x
- P/B
- 3.77x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 3O8.F undervalued?
Graham number3O8.F trades 54.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Omeros Corporation fundamental analysis
No fundamental analysis for Omeros Corporation yet.
Omeros Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also deve…
Full company profileOmeros Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Omeros Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 41.6M | 64.8M | 29.9M | 112M | 73.8M | 90.5M | 0.00 | 0.00 | 0.00 | 0.00 | 76.8M |
| Gross Profit | 40.2M | 63.7M | 29.4M | 111M | 72.9M | 89.5M | - | - | - | - | 74.1M |
| Operating Income | -54.3M | -43.9M | -112M | -63.4M | -111M | -174M | -163M | -165M | -167M | -123M | -34.7M |
| EBITDA | - | -41.9M | -122M | -60.0M | -122M | -170M | -159M | -143M | -155M | -122M | 144M |
| Net Income | -66.7M | -53.5M | -127M | -84.5M | -138M | 194M | 47.4M | -118M | -157M | -3.35M | 139M |
| EPS | - | -1.11 | -2.59 | -1.56 | -2.24 | 3.10 | 0.75 | -1.93 | -2.71 | -0.05 | 1.92 |
| Balance Sheet | |||||||||||
| Total Assets | 67.3M | 116M | 95.9M | 137M | 181M | 419M | 591M | 378M | 277M | 326M | 287M |
| Total Liabilities | 105M | 119M | 196M | 246M | 302M | 395M | 505M | 403M | 460M | 447M | 338M |
| Shareholders' Equity | -37.4M | -2.81M | -100M | -109M | -121M | 23.8M | 85.7M | -25.0M | -183M | -121M | -51.3M |
| Cash & Short-term Investments | 2.22M | 3.39M | 5.86M | 3.08M | 10.5M | 101M | 11.0M | 7.11M | 3.40M | 9.66M | 1.99M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -51.5M | -36.2M | -104M | -60.1M | -100M | -110M | -86.5M | 84.2M | -149M | -116M | -20.7M |
| Capital Expenditure | 126K | 350K | 567K | 334K | 283K | 277K | 113K | 321K | 165K | 65.0K | 0.00 |
| Free Cash Flow | - | -36.6M | -104M | -60.4M | -100M | -110M | -86.6M | 83.8M | -149M | -116M | -20.8M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | 816.8% | 55.3% | - | - | - | - |
| ROA | -99.2% | -46.0% | -132.1% | -61.7% | -76.3% | 46.3% | 8.0% | -31.1% | -56.6% | -1.0% | 48.3% |
| Net Profit Margin | -160.4% | -82.5% | -424.4% | -75.6% | -187.0% | 214.6% | - | - | - | - | 180.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Omeros Corporation dividends
Omeros Corporation has not paid dividends in the last 9 fiscal years.
Who owns Omeros Corporation
- Insiders 4.08%
- Institutions 52.51%
- Public & others 43.41%
- Shares outstanding 72.4M
- Free float 69.3M
Omeros Corporation company profile
- Company name
- Omeros Corporation
- Ticker
- 3O8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 175
- Fiscal year end
- December
- Address
- The Omeros Building, Seattle, WA, United States, 98119
- Phone
- 206 676 5000
- Website
- omeros.com
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation management
9- Dr. Gregory A. Demopulos M.D.Co-Founder, Chairman, CEO & President · born 1959
- Mr. David J. BorgesVP of Finance, Chief Accounting Officer & Treasurer · born 1965
- Mr. Peter B. Cancelmo J.D.VP, General Counsel & Corporate Secretary · born 1979
- Dr. Pamela Pierce Palmer M.D., Ph.D.Co-Founder · born 1963
- Dr. George A. Gaitanaris M.D., Ph.D.Chief Scientific Officer & VP of Science · born 1957
- Mr. Peter W. WilliamsVice President of Human Resources · born 1968
- Dr. Catherine A. Melfi Ph.D.Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems · born 1959
- Mr. David W. GhesquiereVP & Chief Business Development Officer · born 1967
- William E. WoodmanVP & Chief Commercial Officer